Chester County News and Community Website
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported a 68% tumor response rate and median progression-free survival of 16 months at the higher dose of its experimental lung …
ArriVent Lung Cancer Drug Shows 68% Response Rate in Trial Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has completed enrollment of 102 patients in a European clinical study evaluating longer versions of its dissolvable magnesium coronary scaffold, advancing research into …
Teleflex Completes Enrollment in Coronary Scaffold Trial Read More
WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) has entered a clinical trial collaboration with Eli Lilly and Co. to evaluate an experimental breast cancer treatment alongside two Lilly drugs, …
Prelude Partners With Lilly to Test Breast Cancer Drug Combinations Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) has dosed the first patient in a U.S. Phase 1 clinical trial of ARR-002, an experimental antibody-drug conjugate targeting ovarian and …
ArriVent Advances Cancer Drug Pipeline With First U.S. Trial Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that more than 70% of patients receiving its oral psoriasis treatment ICOTYDE maintained clear or almost clear skin through two …
Johnson & Johnson Reports Sustained Psoriasis Drug Response Read More
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported additional clinical evidence that its experimental hypertension drug lorundrostat can lower blood pressure in patients whose condition remains uncontrolled despite multiple …
Mineralys Drug Lowers Blood Pressure but Misses Sleep Apnea Goal Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) said its experimental lung cancer drug firmonertinib failed to significantly improve progression-free survival compared with chemotherapy in a pivotal Phase 3 …
ArriVent’s Lung Cancer Drug Fails Key Phase 3 Trial Endpoint Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) reported that its liver disease drug Rezdiffra improved measures of liver damage across patients carrying common genetic risk variants for metabolic dysfunction-associated …
Madrigal Study Finds Rezdiffra Benefits Across Genetic Risks Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its oral psoriasis treatment ICOTYDE (icotrokinra) maintained skin clearance through 112 weeks in a Phase 3 clinical study, providing …
Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that adolescents with generalized myasthenia gravis maintained improvements in daily function and muscle strength through two years of IMAAVY treatment, …
J&J’s IMAAVY Maintains Gains in Two-Year Adolescent Study Read More